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Abstract
Background: It has been suggested that cysteinyl leukotrienes (cysLTs) play an important role in
airway remodeling. Previous reports have indicated that cysLTs augment human airway smooth
muscle cell proliferation. Recently, cysLTs have been measured in exhaled breath condensate
(EBC). The aim of this study was to evaluate the relationship between cysLTs in EBC and another
marker of airway remodeling, reticular basement membrane (RBM) thickening, in endobronchial
biopsies in children.
Methods:  29 children, aged 4–15 years, with moderate to severe persistent asthma, who
underwent bronchoscopy as part of their clinical assessment, were included. Subjects underwent
spirometry and EBC collection for cysLTs analysis, followed by bronchoscopy and endobronchial
biopsy within 24 hours.
Results:  EBC cysLTs were significantly lower in asthmatic children who were treated with
montelukast than in those who were not (median (interquartile range) 36.62 (22.60–101.05) versus
249.1 (74.21–526.36) pg/ml, p = 0.004). There was a significant relationship between EBC cysLTs
and RBM thickness in the subgroup of children who were not treated with montelukast (n = 13, r
= 0.75, p = 0.003).
Conclusion: EBC cysLTs appear to be associated with RBM thickening in asthma.
Background
Inflammation and remodeling are characteristics of the
asthmatic airway. Until recently, remodeling was consid-
ered to be caused by longstanding inflammation, but this
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hypothesis has now begun to be questioned. Structural
changes of remodeling have been found in childhood [1-
3] and recently it has been shown that reticular basement
membrane (RBM) thickening, a characteristic feature of
remodeling, is present in children with difficult asthma to
a similar extent to that seen in adults with asthma [3].
Studies in children are needed to explore the pathophysi-
ology of airway remodeling in early life. However, bron-
choscopy and endobronchial biopsy are not routine
procedures in the management of childhood asthma.
Therefore, non-invasive methods may help in studying
airway remodeling in a similar way to those developed to
investigate airway inflammation using exhaled nitric
oxide, induced sputum or exhaled breath condensate
(EBC).
Measurement of cysteinyl leukotrienes (cysLTs) in EBC
could be one such potential non-invasive method of stud-
ying airway remodeling. CysLTs have been reported to
play an important role in airway remodeling in asthma,
with one study indicating that the cysLT1-receptor antago-
nist montelukast reduces airway smooth muscle cell
hyperplasia and subepithelial fibrosis in ovalbumin-sen-
sitised and -challenged mice [4]. In addition, cysLTs can
be detected in EBC, with elevated levels reported in adults
and children with asthma [5,6].
We measured EBC cysLTs in a group of children with
moderate to severe persistent asthma undergoing bron-
choscopy. We investigated whether cysLTs in EBC are
lower in those patients taking regular montelukast, in
addition to inhaled corticosteroids. In view of a potential
role of cysLTs in airway remodeling, we examined the rela-
tionship between cysLTs in EBC and RBM thickness in
endobronchial biopsies.
Methods
Patients
We recruited 29 children with moderate to severe persist-
ent asthma who underwent bronchoscopy including
endobronchial biopsy as part of their clinical assessment.
Asthma was diagnosed according to American Thoracic
Society (ATS) guidelines [7]. Moderate to severe persistent
asthma was characterised by "daily symptoms despite
>400 µg of inhaled budesonide (or equivalent)" [8]. 21/
29 asthmatic children received additional treatment with
systemic corticosteroids before bronchoscopy; of these 14
patients have been included into our difficult asthma pro-
tocol receiving a corticosteroid trial with either 2 weeks of
prednisolone 40 mg/day (n = 8) or a single intramuscular
injection of triamcinolone 80 mg (n = 6) before bron-
choscopy [9]. Two patients had been prescribed systemic
steroids for worsening of symptoms in the previous 2
weeks and 6 patients were using a long-term maintenance
therapy with prednisolone up to 20 mg/day (table 1).
Study design
Subjects underwent spirometry and EBC collection, fol-
lowed by bronchoscopy including endobronchial biopsy
within 24 hours. Atopy was diagnosed if serum specific
IgE (>0.34 kU/l) was raised or skin prick test was positive
(wheal >2 mm larger than negative control) to at least one
more antigen (D. pteronyssinus, cat, dog, grass pollen,
Aspergillus fumigatus). Measurements of EBC and RBM
thickness were done blind.
The study was approved by the Ethics Committee of the
Royal Brompton and Harefield Hospital National Health
Service Trust and written informed consent was obtained
from all parents and children recruited into the study.
Spirometry
Spirometry (Compact Vitalograph, Vitalograph Ltd, Buck-
ingham, UK) was performed at baseline according to ATS
guidelines [10]. Patients were asked to withhold short-act-
ing bronchodilator for 4 hours prior to spirometry, if pos-
sible.
Exhaled breath condensate
We collected EBC using a commercially available con-
denser (EcoScreen, Jaeger, Würzburg, Germany) accord-
ing to the current ATS/ERS guidelines, as previously
described [11,12]. Samples were immediately stored at -
80°C. CysLTs (LTC4, LTD4 and LTE4) concentrations were
analysed by a specific enzyme immunoassay (Cayman
Chemical, Ann Arbor, MI). The lower limit for detection
was 11.0 pg/ml and the upper limit was 700 pg/ml.
Fiberoptic bronchoscopy and sample processing
Bronchoscopy with endobronchial biopsy was performed
under general anesthesia as previously described [13].
Table 1: Patients' characteristics
Number 29
Age (years) 10.2 (4–15)
Male, n 16
Atopic*, n 21
Duration of symptoms (years) 10.0 (5.0–12.0)
FEV1 (% predicted)# 80 (64–91)
Treatment in previous 2 weeks
Inhaled steroid dosage (budesonide 
equivalent) (µg/day)
2000 (1000–2000)
Budesonide, n 7
Fluticasone, n 22
Oral and/or i.m. steroids, n 21
Long acting bronchodilator 28
Theophylline, n 1
Montelukast, n 14
Age data are expressed as mean (range). Other data are expressed as 
median (interquartile range) or absolute numbers (n).
*No data in 3 asthmatic children, # no data in five children who did 
not cooperate or could not withheld short-acting bronchodilator for 
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Biopsies were taken from the subcarinae of the right lower
lobe and processed into paraffin blocks. 5 µm sections
were cut and stained with haematoxylin and eosin. Using
light microscopy at × 400 magnification, coded sections
were assessed for RBM thickness by a single observer
(C.L.) using computer-aided image (NIH image 1.55,
Maryland, US) as previously described [14]. 40 measure-
ments were done at 20 µm intervals, RBM thickness was
expressed as the geometric mean of the 40 measurements.
Statistical analyses
All analyses were performed using the Statistical Package
of the Social Sciences (SPSS). Comparison between
groups was made using the Fisher's exact test and Mann
Whitney U test as appropriate. Correlations were meas-
ured using Spearman rank correlation. P values < 0.05
were considered statistically significant.
Results
Details of the subjects are shown in table 1. CysLTs in EBC
were detectable in 24/29 asthmatic patients. Five subjects
had values outside the limits of detection (3 were above,
2 below) and could therefore not be included into statis-
tical analysis.
Suitable biopsies for the assessment of RBM thickness
were obtained from 27 children. The median (interquar-
tile range (IQR)) value was 8.78 (7.76–10.42) µm. There
was no significant relationship between the inhaled ster-
oid dose and RBM thickness (r = -0.25, p = 0.21) and there
was no difference in RBM thickness whether patients
received systemic steroids or not (p = 0.48).
Analysis of asthmatic subgroups
Ten of 24 subjects from whom we obtained EBC values
were taking montelukast (5–10 mg daily according to the
patients' age). There was no significant difference in age,
atopic status, inhaled steroid dosage, FEV1 or treatment
with systemic steroids between patients who were and
were not prescribed montelukast. CysLTs in EBC were sig-
nificantly lower in asthmatic children treated with monte-
lukast than in those who were not (median (IQR) 36.62
(22.60–101.05) vs. 249.1 (74.21–526.36) pg/ml, p =
0.004, figure 1). RBM thickness did not differ significantly
between the two groups (p = 0.923, figure 2).
Relationship between cysLTs in EBC and RBM thickness in 
endobronchial biopsies
Both suitable biopsies and measurable cysLTs levels in
EBC were obtained in 22 children. There was a trend only
for a significant relationship between cysLTs levels in EBC
and RBM thickness measured in endobronchial biopsies
in the group as a whole (r = 0.37, p = 0.09) (figure 3).
However, there was a significant relationship between
these two markers in a subgroup of children who were not
additionally treated with montelukast (n = 13, r = 0.75, p
= 0.003) (figure 3).
Discussion
We have shown that exhaled cysLTs are detectable in chil-
dren with moderate to persistent asthma with signifi-
cantly lower concentrations in children who were
additionally treated with montelukast compared to chil-
dren who were not treated with montelukast. The princi-
pal finding of this study is that cysLTs in EBC correlated
significantly with RBM thickness measured in endobron-
chial biopsies in a subgroup of asthmatic children who
were not treated with montelukast. At the present time, we
are not aware of any other study which has addressed
these questions.
Csoma et al. have reported that cysLTs were detectable in
all 13 children with moderate to severe persistent asthma
who were included in their study, but no influence of
montelukast was investigated since this drug was not
given to any of the patients [6]. In our study, we have
shown for the first time that the median exhaled cysLTs
concentration was significantly lower in children who
were treated with montelukast than in children who were
not. In keeping with this Volovitz et al. have shown that
montelukast treatment was associated with lower levels of
cysLTs measured in nasal lavage of asthmatic children
[15]. In an adult study Biernacki et al. found that exhaled
cysLTs were significantly reduced after 4 weeks of treat-
ment with montelukast [16]. Possible reasons for this are
not clear, since this drug inhibits cys-LT1 receptors which
should not affect the synthesis of cysLTs. However, recent
evidence suggests that montelukast may have an inhibi-
tory effect on cysLTs synthesis through an inhibitory effect
on 5'-lipoxygenase, an essential enzyme in the biosynthe-
sis of leukotrienes in addition to its antagonism of its
receptors [17].
Several studies have indicated that cysLTs play a role in the
pathophysiology of remodeling [18]. In vitro studies have
shown that LTD4  augments epidermal growth factor-
induced human airway smooth muscle proliferation [19]
and that LTC4 upregulates collagenase expression and syn-
thesis in human lung fibroblasts [20]. Furthermore ani-
mal models have shown that an increase in airway
smooth muscle cells observed in allergen-treated Brown
Norway rats was reduced by cysLT1 receptor antagonism
[21]. In a recent mouse model Henderson et al. found that
montelukast reduces airway smooth muscle cell hyperpla-
sia and subepithelial fibrosis in ovalbumin-sensitised and
-challenged mice [4]. In an open follow up study of seven
asthmatic children low density areas at high resolution
computerized tomography disappeared in six patients
four years after additional treatment with montelukast
suggesting that subepithelial fibrosis and air trapping mayRespiratory Research 2006, 7:63 http://respiratory-research.com/content/7/1/63
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have been reduced by leukotrienes receptor antagonist
treatment [22]. However, to our knowledge there are no
human biopsy studies published so far supporting the
role of cysLTs in airway remodeling.
In this study we have shown for the first time a possible
relationship between cysLTs in EBC and an important fea-
ture of airway remodeling, namely RBM thickening, in
asthmatic children. However, a significant correlation
between cysLTs and RBM thickness was only present in
subjects who were not treated with montelukast. This
might be explained by the effects of montelukast on the
cysLTs production, discussed above. The fact that treat-
ment may perturb a relationship such as the one between
cysLTs and RBM thickening is unsurprising. For example,
the association between exhaled nitric oxide and eosi-
nophilic airway inflammation measured directly is
strongest in subjects not treated with anti-inflammatory
treatment, or in asthmatics who are relatively insensitive
to the effects of corticosteroids [9,23].
In order to study the relationship between cysLTs and
RBM thickness and the use of exhaled cysLTs as a marker
of airway remodeling further biopsy studies should be
planned. Measurement of exhaled cysLTs and RBM thick-
ness before and after a treatment with montelukast would
be useful. However, the design of any study requiring
repeat performance of bronchoscopy and endobronchial
biopsy in order to obtain longitudinal data would be
problematic.
There are a number of limitations to the current study.
Firstly, only a relatively small number of a highly selected
group of patients, those who underwent bronchoscopy
for clinical indications, were tested, so the conclusions
cannot be generalised to all children with asthma. The
study should be regarded as a pilot study, hypothesis-gen-
erating, rather than definitive. Studies involving a larger
sample size would be useful, although the numbers of
subjects undergoing bronchoscopy and biopsy are always
likely to be limited. Secondly, most patients were treated
with high doses of inhaled and/or systemic steroids.
Therefore, it is possible that cysLTs values in EBC would
have been altered by the treatment. However, the influ-
ence of corticosteroids on cysteinyl leukotrienes is contro-
versial. Dworski et al. found that treatment with oral
prednisolone, while reducing asthma symptoms, had no
effect on LTE4 concentration in bronchoalveolar lavage
fluid [24]. Sebaldt et al. found that oral prednisolone had
no effect on urinary LTE4 levels [25]. In contrast Baraldi et
al. reported that cysLTs in EBC were reduced after a course
of oral steroids given for an asthma exacerbation [26].
However, whether cysLTs in EBC are reduced after a ster-
oid trial independently of an asthma exacerbation could
Relationship of reticular basement membrane (RBM) thick- ness to montelukast therapy Figure 2
Relationship of reticular basement membrane (RBM) thick-
ness to montelukast therapy. There was no significant differ-
ence between children treated with montelukast and those 
who were not.
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to montelukast therapy. Open symbols indicate patients 
without systemic steroids. Levels were significantly lower in 
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not be studied. We acknowledge as well that prolonged
high dose steroids may affect basement membrane thick-
ness to a degree [27-29]. However, some studies do not
support a role for corticosteroids in reducing airway
remodeling [30,31]. However, again, the design of a study
including patients who are not on steroids but undergo
bronchoscopy would be problematic due to ethical con-
siderations.
We acknowledge that our study is of cross-sectional obser-
vations, analysed by using coefficients of correlation. This
limits the strength of the conclusions which can be drawn,
and means that the study is hypothesis generating in
many respects. Correlation analyses cannot prove either
the presence or the direction of causality; this can only be
done by appropriately designed, longitudinal studies. Fur-
thermore, as a general point, statistically significant results
may not necessarily be clinically relevant. Also, associa-
tions which are significant for groups may not be suffi-
ciently sensitive to be used as a clinical tool for decision
making in individual patients.
Another weakness is that we were unable to obtain data
on the variability of repeated measurements of cysLTs and
RBM thickness over time, due to ethical constraints for
RBM thickness in particular. We have previously reported
within-subject variability for RBM thickness in biopsies
[32].
The cysLTs values in EBC were in general higher in our
study in comparison to other studies [26,33]. This might
be explained by the highly selected nature of the patients
in our study. However, it has been noted that compari-
sons of data obtained in different laboratories are cur-
rently difficult because of the lack of standardised
procedure for validated analytic techniques [11]. EBC
analysis seems to be more reliable for making compari-
sons between groups, rather than for determining abso-
lute levels of mediators [33].
Conclusion
The goals of asthma therapy include prevention both of
inflammation and structural airway wall changes.
Whereas we have a number of non-invasive tools to meas-
ure inflammation (EBC, induced sputum, exhaled
breath), non-invasive assessment monitoring of remode-
ling is much more difficult. This is the first study to inves-
tigate the relationship between cysLTs in EBC and one of
the characteristic features of airway remodeling in asthma,
RBM thickening. The data demonstrate an association
between cysLTs and RBM thickening in those subjects not
treated with montelukast. The use of measurements of
cysLTs in EBC as a non-invasive marker of RBM thickening
may be worth further investigation. If possible, future
studies should include a larger number of children not
Table 2: Corticosteroid therapy according to a treatment with montelukast
Patients treated with Montelukast (n = 14) Patients not treated with Montelukast (n = 15)
No systemic steroids 2 6
Prednisolone 7 9
• Maintenance therapy* 4 2
• 2 weeks course of prednisolone 40 mg/day 2 6
• Short course of prednisolone because of 
worsening of symptoms
11
Triamcinolone (one single i.m. injection) 5 1
* one child had triamcinolone and was on maintenance prednisolone therapy
Relationship between exhaled cysteinyl leukotrienes (cysLTs)  values and reticular basement membrane (RBM) thickness in  endobronchial biopsies Figure 3
Relationship between exhaled cysteinyl leukotrienes (cysLTs) 
values and reticular basement membrane (RBM) thickness in 
endobronchial biopsies. Open symbols indicate patients with-
out montelukast. There was a significant relationship 
between cysLTs levels in EBC and RBM thickness measured 
in endobronchial biopsies in the subgroup of patients who 
were not treated with montelukast (r = 0.75, p = 0.003).Respiratory Research 2006, 7:63 http://respiratory-research.com/content/7/1/63
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treated with montelukast or systemic steroids. The design
of such studies will require careful planning, in view of the
ethical considerations. However, the validation of non-
invasive methods of monitoring asthma in childhood will
only be possible through the initial inclusion of invasive
methods for comparison.
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